Compare Inovio Pharmaceuticals Inc (INO) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vale SA — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Vale SA trades at $14.26 (market cap $59.07B). The key difference: Vale SA is far larger — about 661.7× Inovio Pharmaceuticals Inc's market cap, and Vale SA pays a 8.93% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | VALE | |
|---|---|---|
Market Cap | $89.27M | $59.07B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $17.82 |
52-Week Low | $1.05 | $9.53 |
Enterprise Value | $60.28M | $75.99B |
Dividend Yield | — | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
VALE trades at $14.08, down 0.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported $38.4B revenue for 2025 with net income of $2.35B, though earnings have missed expectations in two of the last three quarters. Recent news highlights governance challenges and a $2.6B decarbonization investment plan announced in June 2026.
While analyst consensus remains cautiously optimistic with a $17.63 price target, declining profit margins and recent earnings misses present headwinds. The stock offers value with reasonable P/E and EV/EBITDA multiples, but investors face risks from commodity price volatility and execution challenges in the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
